DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy
and safety of tigecycline versus imipenem/cilastatin in
patients with complicated intra-abdominal infections. BMC
Infect Dis, 2005, 5:88.
Parry CM. Antimicrobial drug resistance in Salmonella enterica.
Curr Opin Infect Dis, 2003, 16:467–472.
Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions
of macrolides. Clin Pharmacokinet, 1992, 23:106–131.
Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin
to prevent postoperative Staphylococcus aureus infections.
N Engl J Med, 2002, 346:1871–1877.
Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective
therapy on the efficacy of daptomycin and ceftriaxone for the
treatment of community-acquired pneumonia. Clin Infect Dis,
2008, 46:1142–1151.
Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo
antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido
derivative of minocycline (GAR-936).
Antimicrob Agents Chemother, 1999, 43:738–744.
Peterson WL, Fendrick AM, Cave DR, et al. Helicobacter
pylori–related disease: Guidelines for testing and treatment.
Arch Intern Med, 2000, 160:1285–1291.
Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis.
N Engl J Med, 1997, 336:708–716.
Ramsey MA, Bradley SF, Kauffman CA, Morton TM.
Identification of chromosomal location of mupA gene, encoding
low-level mupirocin resistance in staphylococcal isolates.
Antimicrob Agents Chemother, 1996, 40:2820–2823.
Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-
100766) versus vancomycin in the treatment of hospitalized
patients with nosocomial pneumonia: a randomized, doubleblind,
multicenter study. Clin Infect Dis, 2001, 32:402–412.
Rybak MJ. The pharmacokinetic and pharmacodynamic properties
of vancomycin. Clin Infect Dis, 2006, 42(suppl):S35–S39.
Rybak MJ, Lomaestro BM, Rotschfer JC, et al. Vancomycin
therapeutic guidelines: a summary of consensus recommendations
from the Infectious Diseases Society of America, the
American Society of Health-System Pharmacists, and the
Society of Infectious Diseases Pharmacists. Clin Infect Dis,
2009, 49:325–327.
San Gabriel P, Zhou J, Tabibi S, et al. Antimicrobial susceptibility
and synergy studies of Stenotrophomonas maltophilia isolates
from patients with cystic fibrosis. Antimicrob Agents
Chemother, 2004, 48:168–171.
Shi J, Montay G, Chapel S, et al. Pharmacokinetics and safety of
the ketolide telithromycin in patients with renal impairment.
J Clin Pharmacol, 2004, 44:234–244.
Sieradzki K, Tomasz A. Gradual alterations in cell wall structure
and metabolism in vancomycin-resistant mutants of
Staphylococcus aureus. J Bacteriol, 1999, 181:7566–7570.
Sieradzki K, Wu SW, Tomasz A. Inactivation of the methicillin
resistance gene mecA in vancomycin-resistant Staphylococcus
aureus. Microb Drug Resist, 1999, 5:253–237.
Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of
daptomycin by pulmonary surfactant: In vitro modeling and
clinical impact. J Infect Dis, 2005, 191:2149–2152.
Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin
resistance in Staphylococcus aureus. Glycopeptide-
Intermediate Staphylococcus aureus Working Group. N Engl
J Med, 1999, 340:493–501.
Soltani M, Beighton D, Philpott-Howard J, Woodford N.
Mechanisms of resistance to quinupristin-dalfopristin among
isolates of Enterococcus faecium from animals, raw meat, and
hospital patients in Western Europe. Antimicrob Agents
Chemother, 2000, 44:433–436.
Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum:
a worldwide sample of 6737 clinical gram-positive
organisms. J Antimicrob Chemother, 2004, 53:669–674.
Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines
for the management of bacterial meningitis. Clin Infect Dis,
2004, 39:1267–1284.
Udo EE, Jacob LE, Mathew B. Genetic analysis of methicillinresistant
Staphylococcus aureus expressing high and lowlevel
mupirocin resistance. J Med Microbiol, 2001, 50:
909–915.
Villareal FJ, Griffin M, Owens J, et al. Early short-term treatment
with doxycycline modulates post-infarction left ventricular
remodeling. Circulation, 2003, 108:1487–1492.
Ward TT, Rimland D, Kauffman C, et al. Randomized, openlabel
trial of azithromycin plus ethambutol vs. clarithromycin
plus ethambutol as therapy for Mycobacterium avium complex
bacteremia in patients with human immunodeficiency virus
infection. Veterans Affairs HIV Research Consortium. Clin
Infect Dis, 1998, 27:1278–1285.
Wareham DW, Wilson P. Chloramphenicol in the 21st century.
Hosp Med, 2002, 63:157–161.
Weigel LM, Clewell DB, Gill SR, et al. Genetic analysis of a
high-level vancomycin-resistant isolate of Staphylococcus
aureus. Science, 2003, 302:1569–1571.
Wertheim HF, Vos MC, Ott A, et al. Mupirocin prophylaxis
against nosocomial Staphylococcus aureus infections in nonsurgical
patients: a randomized study. Ann Intern Med, 2004,
140:419–425.
Wilson P, Andrews JA, Charlesworth R, et al. Linezolid resistance
in clinical isolates of Staphylococcus aureus. J Antimicrob
Chemother, 2003, 51:186–188.
Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective
endocarditis: Guidelines from the American Heart Association:
A guideline from the American Heart Association Rheumatic
Fever, Endocarditis and Kawasaki Disease Committee, Council
on Cardiovascular Disease in the Young, and the Council on
Clinical Cardiology, Council on Cardiovascular Surgery and
Anesthesia, and the Quality of Care and Outcomes Research
Interdisciplinary Working Group. J Am Dent Assoc, 2007,
138:739–745, 747–760.
Workowski KA, Berman SM. Sexually transmitted diseases treatment
guidelines, 2006. MMWR, 2006; 55(RR-11):1–94. Available
at: www.cdc.gov/mmwr/preview/ mmwrhtml/ rr5511a1.htm.
Accessed December 16, 2009.
Wunderink RG, Cammarata SK, Olliphant TH, et al.
Continuation of a randomized, double-blind, multicenter study
of linezolid versus vancomycin in the treatment of patients
with nosocomial pneumonia. Clin Ther, 2003a, 25:980–992.
Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs.
vancomycin: analysis of two double-blind studies of patients
with methicillin-resistant Staphylococcus aureus nosocomial
pneumonia. Chest, 2003b, 124:1789–1797.
Yang S-J, Xiong YQ, Schrenzel J, et al. Regulation of mprF in
daptomycin-nonsusceptible Staphylococcus aureus strains.
Antimicrob Agents Chemother, 2009, 53:2636–2637.
1547
CHAPTER 55
PROTEIN SYNTHESIS INHIBITORS AND MISCELLANEOUS ANTIBACTERIAL AGENTS